retatrutide clinical development This data from Phase 3 trials for was announced yesterday at @amdiabetesassn #ADA2026 ✓ We are fortunate to be living in a time where there multiple medications which safely reduce TRIUMPH-1 Trial Results Show Promising

Al final del estudio los pacientes del grupo de 3,0 mg/da de la liraglutida perdieron en promedio 6,4 kg (6,0%), los de 1,8 perdieron en promedio 5,0 kg (4,7%), mientras los del grupo placebo perdieron 2,2 kg (2,0%)

Further contributing to the context of ECM remodeling, TIMP1 and TIMP2, key inhibitors of MMPs, were also downregulated in the secretome of stressed cells

And so when you have a patient in your office, one, as a primary care frontline doctor, its very important to understand, if you dont set up the patient for success, they will not be successful on bariatric surgery

The GLP-1 era is here but your clinical leadership will determine whether patients merely lose weight or truly reprogram their metabolism